Bank of America Merrill Lynch cross‑asset trade idea list and closed trades (2016)
Summary
The document contains only internal trading recommendations and execution dates with analyst names. It lacks any connection to political figures, government agencies, financial misconduct, or novel in Indicative pricing for a range of cross‑asset strategies as of Jan‑29‑2016. List of closed trades with analyst identifiers and trade dates. Sources cited as BofA Merrill Lynch Global Research and Blo
This document is from the House Oversight Committee Releases.
View Source CollectionPersons Referenced (1)
Tags
Related Documents (6)
Confidential Global Utility Sector White Paper – Hedge Fund Positioning Data (2013)
The document provides internal banking survey data on hedge fund exposure to the global utilities sector, but it does not name any high‑profile individuals, government agencies, or foreign leaders. Th Bank of America Merrill Lynch survey shows utilities were heavily underweight by hedge funds in 2012 Long/short ratio for utilities fell from 3.0x (Jan 2008) to 1.7x (Jan 2012) then rose 60% to 2.7x.
New Leaf Venture Partners outlines investment strategy for NLV-III fund
The passage provides a standard venture capital fund investment overview with no mention of specific high‑profile individuals, government agencies, or controversial transactions. It lacks actionable l Fund targets biopharma, information convergence, medical devices, and research tools. Plans to invest in 24‑28 companies, primarily US‑based. Fund managers intend to serve on board seats and influenc
New Leaf Fund Investment Strategy Overview for Late-Stage Biotech Companies
The passage outlines a private fund's investment focus on late‑stage biotech firms and lists several portfolio companies. It contains no direct references to high‑ranking officials, government agencie Fund targets companies nearing regulatory approval and commercial profitability. Focus on small‑cap public and private biotech firms with low clinical risk. Examples of past investments: Acadia Pharm
Closed Trades Summary – June 2017 Options and Futures Positions
The document is a routine internal trading log detailing option and futures positions, trade rationales, and market commentary. It contains no references to high‑ranking officials, government agencies Lists specific option spreads, strikes, and expirations for equities, indices, and commodities. Provides trade rationales tied to earnings releases, macro events (BoJ, Fed, EU stress tests), and p Sh
Internal email discussing failed options trades and alleged mismanagement at Alpha Group Capital
The passage contains a private correspondence about trading mistakes and personal grievances. It mentions no high‑ranking officials, government bodies, or significant financial flows beyond a small tr Email from Jeffrey (jeevacation@gmail.com) to Paul Barrett of Alpha Group Capital LLC. Discusses August and September put options with prices $4.10 and $7.90 respectively. Accusations of amateur trad
Financial Trade Strategy: Buying XLF Calls Financed by Selling QQQ Calls
The passage only discusses a market trade idea and volatility metrics without mentioning any high‑profile individuals, government bodies, or controversial financial flows. It offers no actionable lead Suggests buying 1‑month XLF ATM calls funded by selling 1‑month QQQ ATM calls. References post‑FOMC market expectations of a hawkish Fed and stronger USD. Provides historical volatility and correlati
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.